PAVmed to Hold Business Update Conference Call and Webcast on December 7th

NEW YORK–(BUSINESS WIRE)– PAVmed Inc. (Nasdaq:PAVM,PAVMW), a highly differentiated,
multi-product medical device company, today announced financial results
for the third quarter ended September 30, 2016 and that the Company will
host a conference call on December 7, 2016 at 4:30 p.m. Eastern time.

During this call, PAVmed’s Chairman and Chief Executive Officer Lishan
Aklog, M.D. will provide a business update including an overview of the
Company’s near-term milestones and growth strategy. Christopher J.
Hartnick, M.D. will be joining Dr. Aklog to discuss PAVmed’s recently
announced partnership with a group of leading academic institutions to
develop and commercialize a revolutionary device to treat ear
infections. The device, called DisappEAR™, is an antibiotic-eluting
resorbable ear tube based on a proprietary aqueous silk technology. Dr.
Hartnick, who recently joined PAVmed’s Medical Advisory Board, is one of
the visionaries behind this technology and serves as Professor of
Otolaryngology at Harvard Medical School and Chief of Pediatric
Otolaryngology at Massachusetts Eye and Ear Infirmary and Massachusetts
General Hospital.

“We continue to make solid progress in advancing our product pipeline
towards clearance and commercialization. The addition of our sixth lead
product, and our first to be developed and commercialized in partnership
with leading outside institutions, is a very important milestone for our
company,” Dr. Aklog said. “It is consistent with our growth strategy of
building an expanding multi-product pipeline of innovative products
addressing unmet clinical needs, which we believe have attractive
regulatory pathways and market opportunities and encompass a broad
spectrum of clinical areas,” he added.

For the three and nine months ended September 30, 2016, the Company
incurred $578,474 and $1,112,616 of research and development costs,
respectively, and $1,350,248 and $2,827,721 of formation and operating
costs, respectively. Cash was $1,788,650 at September 30, 2016.

Full third quarter financial results can be obtained from the Company’s
investor relations website here
or directly from the SEC website here.

To access the conference call, U.S.-based listeners should dial (844)
666-7591 and international listeners should dial (443) 961-0431. All
listeners should provide the following passcode: 30329780. Individuals
interested in listening to the live conference call via the Internet may
do so by logging on to the Company’s website at www.pavmed.com.

Following the conclusion of the conference call, a replay will be
available through December 13, 2016 and can be accessed by dialing (855)
859-2056 from within the U.S. or (404) 537-3406 from outside the U.S.
All listeners should provide passcode 30329780.

About PAVmed

PAVmed Inc. (Nasdaq:PAVM, PAVMW) is a highly differentiated,
multi-product medical device company employing a unique business model
designed to advance products from concept to commercialization much more
rapidly and with significantly less capital than the typical medical
device company. This proprietary model enables PAVmed to pursue an
expanding multi-product pipeline strategy with a view to enhancing and
accelerating value creation. PAVmed’s diversified pipeline of products
address unmet clinical needs, have attractive regulatory pathways and
market opportunities and encompass a broad spectrum of clinical areas
including carpal tunnel syndrome (CarpX™), medical infusions (NextFlo™
and NextCath™), interventional radiology (PortIO™ and NextCath), tissue
ablation and cardiovascular intervention (Caldus™) and pediatriac ear
infections (DisappEAR™). The Company intends to further expand its
pipeline through engagements with clinician innovators and leading
academic medical centers. For further information, please visit www.pavmed.com.

Forward-Looking Statements

This press release includes forward-looking statements that involve
risks and uncertainties. Forward-looking statements are statements that
are not historical facts. Such forward-looking statements, based upon
the current beliefs and expectations of the Company’s management, are
subject to risks and uncertainties, which could cause actual results to
differ from the forward-looking statements. Risks and uncertainties that
may cause such differences include, among other things, the
uncertainties inherent in research and development, including the cost
and time required advance our products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and results
from our pre‐clinical studies; whether and when our products are cleared
by regulatory authorities; market acceptance of our products once
cleared and commercialized; our ability to raise additional funding and
other competitive developments. PAVmed has not yet sought or received
clearance from the FDA or other regulatory body to market any of its
products. New risks and uncertainties may arise from time to time and
are difficult to predict. All of these factors are difficult or
impossible to predict accurately and many of them are beyond our
control. For a further list and description of these and other important
risks and uncertainties that may affect our future operations, see Part
I, Item IA, “Risk Factors,” in our most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, as the same may
be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Reports
on Form 10-Q filed by us after our most recent Annual Report. We
disclaim any intention or obligation to publicly update or revise any
forward-looking statement to reflect any change in our expectations or
in events, conditions, or circumstances on which those expectations may
be based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161202005161/en/